•
Cell and gene therapy (CGT) specialist Biosyngen Pte Ltd has announced receiving approval from the US FDA to initiate a Phase I/II clinical study for its BRG01, an autologous T cell therapy for the treatment of relapsed/metastatic nasopharyngeal cancer (NPC). This marks a significant milestone in the development of innovative…
•
The national drug alliance procurement office has released a notification initiating the drug information filing process for the 8th volume-based procurement (VBP) round. This round is a significant step in the ongoing efforts to streamline and optimize the procurement of pharmaceuticals in China. Registration and Information SubmissionAs of February 20,…
•
Shanghai-based BRL Medicine Inc. has announced a significant breakthrough in the treatment of thalassemia major. The company reported the first cure in a multi-center Phase clinical study assessing the safety and efficacy of its BRL-101, an autologous hematopoietic stem progenitor cell therapy. This marks a major milestone in the development…
•
China-based Immuno Cure BioTech has announced the initiation of a Phase I clinical study for its ICVAX, a therapeutic vaccine against HIV/AIDS, in Shenzhen. This marks a significant step forward in the development of innovative treatments for HIV/AIDS, a condition that affects millions of people globally. Study Design and ObjectivesThe…
•
China-based Clover Biopharmaceuticals, Ltd (HKG: 2197) has announced an exclusive agreement with Adimmune Corporation for the distribution of AdimFlu-S (QIS) in mainland China. AdimFlu-S (QIS) is the only imported quadrivalent seasonal influenza vaccine approved for use in individuals aged three years and older in China. The agreement also grants Clover…
•
China-based Hainan Honz Pharmaceutical Co., Ltd (SHE: 300086) has entered into a three-year partnership with Indonesia’s Global Putra International (GPI). The strategic collaboration is focused on multiple fronts, aiming to expand Hainan Honz’s pediatric and maternity medicines into overseas markets through the Regional Comprehensive Economic Partnership (RCEP) and Hainan free…
•
MoleculeMind, an artificial intelligence (AI)-empowered protein design platform based in Beijing, has reportedly raised over RMB 100 million (USD 14.58 million) in its latest financing round. The round was led by Cathay Biotech Inc. (SHA: 688065), a synthetic biology firm based in Shanghai, with contributions from Lenovo Capital and Sequoia…
•
The Center for Drug Evaluation (CDE) website indicates that China-based Wuhan Binhui Biotechnology Co., Ltd’s GM-CSF oncolytic herpes simplex virus type II (OH2) for injection (Vero cells) has been awarded breakthrough therapy designation (BTD) status. This designation is for the treatment of patients with unresectable or metastatic melanoma who have…
•
The Center for Drug Evaluation (CDE) website indicates that Japan-based Eisai’s (TYO: 4523) lecanemab has been awarded priority review status. The drug falls under the category of “clinically urgent shortage drugs and innovative and modified drugs for the prevention and treatment of major infectious diseases and rare diseases.” This designation…
•
Beijing Chunlizhengda Medical Instruments Co., Ltd (HKG: 1858, SHA: 688236) is poised to acquire a 60.25% stake in Surgimaster Surgical Co., Ltd, a medical power tool products provider based in Suzhou. The transaction, valued at RMB 11 million (USD 1.6 million), is accompanied by an additional RMB 6.5 million (USD…
•
China’s Shanghai Duoning Biotechnology Co., Ltd has entered into a licensing deal with compatriot firm BioAces (Shanghai) Life Science Co., Ltd., obtaining exclusive global rights to the latter’s cell counter products. The products in question include the CytScope PRO and CytScope MINI intelligent cell analyzers, both of which are already…
•
China-based molecular diagnostics specialist Sansure Biotech Inc. (SHA: 688289) has announced a strategic partnership with Hunan Normal University. The collaboration aims to leverage the respective strengths of both entities to delve deeper into talent cultivation, scientific research, and platform co-construction, among other areas. No financial details of the partnership were…
•
Switzerland-based packaging firm Amcor (NYSE: AMCR) has unveiled the signing of a deal to acquire Shanghai-based medical device packaging company MDK. The acquisition gives Amcor control of a company with approximately USD 50 million in annual revenues and adds a manufacturing site to strengthen its presence in the Asia-Pacific region.…
•
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced receiving the go-ahead from the National Medical Products Administration (NMPA) to initiate a clinical study for the antibody drug NBL-020. This marks a significant step forward in the development of new treatments for advanced solid tumors. NBL-020: Anti-Tumor Necrosis Factor Type…
•
China-based Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422) has obtained another indication approval in China for its generic version of BI/Eli Lilly’s Jardiance (empagliflozin). The hypoglycemic agent can now be used to reduce the risk of hospitalization due to heart failure in adult patients with symptomatic chronic heart failure. Jardiance:…
•
Zhejiang-based tumor precision medicine specialist Topgen Biopharm Co., Ltd has entered into a strategic partnership with Fudan University Shanghai Cancer Center. The RMB 31 million (USD 4.5 million) deal will see the two Chinese entities collaborate on the translation of “breast cancer multi-gene detection” technology, marking a significant step forward…
•
China-based By-Health Co., Ltd. (SHE: 300146) has entered into a strategic partnership with Meituan’s drug purchase APP, a leading delivery platform in China. The collaboration aims to leverage the respective strengths of both companies to delve deeper into the new retail sector, focusing on innovation and digital transformation. Expanding Product…
•
China-based Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601) has announced a strategic partnership with a local company in Pakistan. The collaboration aims to work together on the regulatory filing, distribution, and licensing of Kangtai’s 13-valent and 23-valent pneumonia vaccines in the Pakistani market. Pakistan’s Vaccination Plan and Market OpportunityPakistan,…
•
Shanghai-based REMD, a leading manufacturer of irreversible electroporation devices, has reportedly raised over RMB 100 million (USD 14.54 million) in a Series A+ financing round. The round was led by Silicon Paradise Asset Management, with additional investments from DT Capital Partners and Qianzhan Investment. The proceeds will be used to…